Latest Market Reaction News

ARC Funds Limited has withdrawn its scrip offer for the remaining shares in The Term Deposit Shop Pty Ltd after securing acceptances for just over 10% of the target shares, raising its ownership to nearly three-quarters of the company.

The Federal Court of Australia has approved Ideagen’s acquisition of Envirosuite via a scheme of arrangement, setting the stage for a $0.09 per share cash payout to shareholders.

Greatland Resources has downgraded its FY26 gold production target and significantly increased capital expenditure forecasts for its Telfer Project, prompting a sharp share price reaction and detailed ASX disclosure.

Orcoda Limited has clarified the materiality and timing of disclosures related to its ACTA trial and new SaaS contracts, confirming compliance with ASX Listing Rules and explaining the rationale behind its announcements.

Boss Energy has acknowledged significant upward revisions to operating and capital costs at its Honeymoon Uranium Project, alongside challenges in achieving production targets, prompting an independent review.

Macarthur Minerals has successfully raised nearly $2 million through a rights issue, with Gold Valley Yilgarn Pty Ltd underwriting the shortfall and set to become a substantial shareholder pending approval.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

Donaco International shareholders have overwhelmingly approved a scheme of arrangement for On Nut Road Limited to acquire the company at a significant premium, setting the stage for a major ownership change pending court approval.

Pacific Edge has successfully closed its Share Purchase Plan, raising $4.7 million and bringing total new equity to $20.7 million, surpassing initial targets. The capital raise awaits shareholder approval at the upcoming Annual Meeting.

Envirosuite shareholders have decisively approved the proposed acquisition by Ideagen EVS BidCo Pty Limited, moving the deal closer to completion pending final court approval.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

Transurban Group reveals modest participation in its latest Distribution Reinvestment Plan, with new securities priced at $13.4692 ahead of the August payment date.